{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:07:02Z","timestamp":1773842822271,"version":"3.50.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors(ICIs) that activate tumor-specific immune responses bring new hope for the treatment of hepatocellular carcinoma(HCC). However, there are still some problems, such as uncertain curative effects and low objective response rates, which limit the curative effect of immunotherapy. Therefore, it is an urgent problem to guide the use of ICIs in HCC based on molecular typing. We downloaded the The Cancer Genome Atlas-Liver hepatocellular carcinoma(TCGA-LIHC) and Mongolian-LIHC cohort. Unsupervised clustering was applied to the highly variable data regarding expression of DNA damage repair(DDR). The CIBERSORT was used to evaluate the proportions of immune cells. The connectivity map(CMap) and pRRophetic algorithms were used to predict the drug sensitivity. There were significant differences in DDR molecular subclasses in HCC(DDR1 and DDR2), and DDR1 patients had low expression of DDR-related genes, while DDR2 patients had high expression of DDR-related genes. Of the patients who received traditional treatment, DDR2 patients had significantly worse overall survival(OS) than DDR1 patients. In contrast, of the patients who received ICIs, DDR2 patients had significantly prolonged OS compared with DDR1 patients. Of the patients who received traditional treatment, patients with high DDR scores had worse OS than those with low DDR scores. However, the survival of patients with high DDR scores after receiving ICIs was significantly higher than that of patients with low DDR scores. The DDR scores of patients in the DDR2 group were significantly higher than those of patients in the DDR1 group. The tumor microenvironment(TME) of DDR2 patients was highly infiltrated by activated immune cells, immune checkpoint molecules and proinflammatory molecules and antigen presentation-related molecules. In this study, HCC patients were divided into the DDR1 and DDR2 group. Moreover, DDR status may serve as a potential biomarker to predict opposite clinical prognosis immunotherapy and non-immunotherapy in HCC.<\/jats:p>","DOI":"10.3389\/fimmu.2021.676922","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T17:52:27Z","timestamp":1626371547000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Yunfei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youzan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29086","article-title":"AASLD Guidelines for the Treatment of Hepatocellular Carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.12.009","article-title":"Current Progress in Immunotherapy of Hepatocellular Carcinoma","volume":"66","author":"Sprinzl","year":"2017","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3079","article-title":"Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies","volume":"23","author":"Siu","year":"2017","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1535315","article-title":"Nivolumab for the Treatment of Hepatocellular Carcinoma","volume":"18","author":"Finkelmeier","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2017.00511","article-title":"Effects of Outcome Predictability on Human Learning","volume":"8","author":"Griffiths","year":"2017","journal-title":"Front Psychol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/153867","article-title":"Involvement of DNA Damage Response Pathways in Hepatocellular Carcinoma","volume":"2014","author":"Yang","year":"2014","journal-title":"BioMed Res Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2217\/nnm.10.35","article-title":"Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress","volume":"5","author":"Dong","year":"2010","journal-title":"Nanomed (Lond)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000449346","article-title":"Hepatocellular Carcinoma: The Role of Interventional Oncology","volume":"6","author":"Donadon","year":"2016","journal-title":"Liver Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41419-018-0575-0","article-title":"Corylin Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy Through Long Noncoding RNA RAD51-AS1-Mediated Inhibition of DNA Repair","volume":"9","author":"Chen","year":"2018","journal-title":"Cell Death Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"16951","DOI":"10.1038\/s41598-018-34855-0","article-title":"Safranal Induces DNA Double-Strand Breakage and ER-Stress-Mediated Cell Death in Hepatocellular Carcinoma Cells","volume":"8","author":"Al-Hrout","year":"2018","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1814","article-title":"Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1\/PD-L1 Blockade in Advanced Urothelial Cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252","article-title":"Comprehensive Molecular Characterization of Human Colon and Rectal Cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5997","article-title":"Mutational Profiling of Colorectal Cancers With Microsatellite Instability","volume":"6","author":"Lin","year":"2015","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: An R\/Bioconductor Package for Integrative Analysis of TCGA Data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1038\/s41467-020-18186-1","article-title":"The Genomic Landscape of Mongolian Hepatocellular Carcinoma","volume":"11","author":"Candia","year":"2020","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: A Class Discovery Tool With Confidence Assessments and Item Tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular Signatures Database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) Hallmark Gene Set Collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature08460","article-title":"Systematic RNA Interference Reveals That Oncogenic KRAS-Driven Cancers Require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling Tumor Infiltrating Immune Cells With CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btm369","article-title":"GSEA-P: A Desktop Application for Gene Set Enrichment Analysis","volume":"23","author":"Subramanian","year":"2007","journal-title":"Bioinformatics"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.neo.2019.04.003","article-title":"Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated With Human Papillomavirus Type 16 Expression, Molecular Features, and Clinical Outcome","volume":"21","author":"Lu","year":"2019","journal-title":"Neoplasia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a Resource for Therapeutic Biomarker Discovery in Cancer Cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B33","volume-title":"Package \u2018survminer.\u2019 Draw Surviv Curves using \u2018ggplot2\u2019(R Packag version 03 1)","author":"Kassambara","year":"2017"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S205633","article-title":"A Novel Mutation Panel for Predicting Etoposide Resistance in Small-Cell Lung Cancer","volume":"13","author":"Qiu","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","article-title":"Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints","volume":"73","author":"Sancar","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"B36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12885-017-3345-y","article-title":"XLF-Mediated NHEJ Activity in Hepatocellular Carcinoma Therapy Resistance","volume":"17","author":"Yang","year":"2017","journal-title":"BMC Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1\/2 Dose Escalation and Expansion Trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet (London England)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105028","article-title":"Age, Sex, and Specific Gene Mutations Affect the Effects of Immune Checkpoint Inhibitors in Colorectal Cancer","volume":"159","author":"Lin","year":"2020","journal-title":"Pharmacol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02039","article-title":"Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer","volume":"11","author":"Lin","year":"2020","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive Genomic Profiling of Upper-Tract and Bladder Urothelial Carcinoma","author":"Necchi","year":"2020","journal-title":"Eur Urol Focus"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0044-z","article-title":"The Immunology of Hepatocellular Carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.6.2613","article-title":"Expression of Fas\/FasL in CD8+ T and CD3+ Foxp3+ Treg Cells\u2013Relationship With Apoptosis of Circulating CD8+ T Cells in Hepatocellular Carcinoma Patients","volume":"15","author":"Guo","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 Axis for Immune Activation -\u00a0A Target for Novel Cancer Therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.06.012","article-title":"A Physiological Function for Ferroptosis in Tumor Suppression by the Immune System","volume":"30","author":"Stockwell","year":"2019","journal-title":"Cell Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02668-8","article-title":"ZFHX3 Mutation as a Protective Biomarker for Immune Checkpoint Blockade in non-Small Cell Lung Cancer","volume":"70","author":"Zhang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(01)00449-4","article-title":"Dendritic Cells: Specialized and Regulated Antigen Processing Machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC Proteins Confer Differential Sensitivity to CTLA-4 and PD-1 Blockade in Untreated Metastatic Melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5702026","article-title":"High Membranous Expression of Fatty Acid Transport Protein 4 Is Associated With Tumorigenesis and Tumor Progression in Clear Cell Renal Cell Carcinoma","volume":"2019","author":"Kim","year":"2019","journal-title":"Dis Markers"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.011","article-title":"A Cholesterol-Based Allostery Model of T Cell Receptor Phosphorylation","volume":"44","author":"Swamy","year":"2016","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3462","article-title":"Inhibition of T Cell Receptor Signaling by Cholesterol Sulfate, a Naturally Occurring Derivative of Membrane Cholesterol","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.676922\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T17:52:32Z","timestamp":1626371552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.676922\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2021.676922"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.676922","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]},"article-number":"676922"}}